Eosinophilic esophagitis associated with infliximab therapy in pediatric patients with inflammatory bowel disease

What is Known The association between tumor necrosis factor antagonist and eosinophilic gastrointestinal disorders, including eosinophilic esophagitis is reported. There is a potential association between the initiation of IFX therapy for some IBD patients and the subsequent development of EoE. What is New This case series of IBD patients who developed eosinophilic esophagitis post‐infliximab (IFX) therapy, highlights their demographic characteristics, clinical features, and comorbidities. IFX might trigger a Th2 cytokine shift, leading to eosinophilic infiltration. Long‐term safety data are needed to identify outcomes in patients who develop eosinophilic esophagitis after treatment with TNF‐alpha antagonists.